Brand Name
Brovana
Generic Name
Arformoterol
View Brand Information FDA approval date: May 31, 2021
Classification: beta2-Adrenergic Agonist
Form: Solution
What is Brovana (Arformoterol)?
BROVANA Inhalation Solution is a long-acting beta 2 -adrenergic agonist indicated for: Long-term, twice daily administration in the maintenance treatment of broncho-constriction in patients with chronic obstructive pulmonary disease , including chronic bronchitis and emphysema.
Approved To Treat
Top Global Experts
There are no experts for this drug
Save this treatment for later
Not sure about your diagnosis?
Related Clinical Trials
There is no clinical trials being done for this treatment
Related Latest Advances
There is no latest advances for this treatment